Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Light color therapy to help chronic pain

Official title: Chromatic Retinal Stimulation to Reduce Chronic Pain and Pain Sensitivity Using Light Bulbs: A Pilot Randomized Crossover Trial

Run by University of North Carolina, Chapel Hill · NCT07825792 · Data updated 2026-11-12

This small crossover study tests whether colored light (S-cone chromatic light) can reduce pain in adults with fibromyalgia or chronic widespread pain compared with white light over two 7-day periods.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment40 (estimated)
SponsorUniversity of North Carolina, Chapel Hill
Academic / other
Locations1 site (Chapel Hill, North Carolina)
StatusRecruiting
StartedNovember 9, 2026
Main results expectedJanuary 1, 2028
Study endsJanuary 1, 2028
Registry record updatedNovember 2, 2026
Trial IDNCT07825792 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with fibromyalgia or chronic widespread pain and fatigue who have persistent pain (average pain ≥4/10) for at least 3 months and meet the specified WPI/SSS criteria.

Probably not a fit

Participants with non-pain-related sleep disturbances or lighting sensitivities, or those unable to adhere to home light exposure requirements, may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In this pilot, randomized, double-blind, crossover trial, adults with fibromyalgia or chronic widespread pain will receive two lighting conditions for 2 hours daily during two separate 7-day periods, with a 1-week washout in between. Participants and study staff are blinded to the light condition, and outcomes include self-reported pain and pain-related interference as well as quantitative sensory testing. The study uses commercially available TUO light bulbs and monitors light intensity to ensure twofold illumination over ambient room light. Baseline assessments cover demographics, validated patient-reported outcomes, and objective pain sensitivity measures; follow-up assessments occur at multiple timepoints across the trial duration (approximately 35 days total).

Why it matters

Potential benefit: If successful, chromatic light therapy could offer a non-pharmacologic option to help reduce pain severity and improve pain processing in these conditions.

How similar studies have gone: Previous small studies suggest light exposure can influence perceptual experiences; this specific chromatic-light approach is exploratory and feasibility-focused.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adults ≥ 18 years of age.
* Individuals who have been diagnosed with fibromyalgia or suffer from chronic widespread pain and fatigue.
* An average pain severity ≥4 on the 0-10 NRS over the month prior to enrollment.
* Pain symptoms present for 3 months or longer.
* Pain must be present in 4 out of 5 body regions.
* A score of ≥7 on the Widespread pain index (WPI) and ≥5 on the symptom severity scale (SSS), or 4-6 on the WPI and ≥9 on the SSS in the 2016 Fibromyalgia Questionnaire.
* Willingness to adjust light levels in home environment so that the illumination (measured in lux) provided by the light bulbs is twice the ambient room illumination (also measured in lux).
* Willingness to use study lightbulbs for 2 consecutive hours a day for 7 consecutive days according to study specifications for both conditions (total of 14 days using lightbulbs)
* Alert and oriented, and able to provide informed consent
* Ability to read and speak English to complete validated questionnaires.

Exclusion Criteria:

* Vision disorders or conditions resulting in severe vision impairment or blindness
* Individuals with self-report of color blindness, uveitis or cataracts.
* Prisoner Status
* Pregnancy
* History of photosensitivity or sensitivity to scintillating (mildly flickering) light.
* History of seizure disorder.
* Individuals living in households with people who have a history of seizure disorders.
* Analgesic treatment plan changes anticipated in the next 3 months (surgery, analgesic medication changes, injections, pain procedures, etc.).
* Other history or condition that would, in the investigator's judgment, indicate that the individual would highly likely be non-compliant with the study or unsuitable for the study

Where it's running

  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina, United States
    Recruiting

Study contacts

  • Principal investigator: Matt Mauck, MD, PhD — UNC Chapel Hill School of Medicine
  • Study coordinator: Matthew Mauck, MD, PhD
  • Email: matt_mauck@med.unc.edu
  • Phone: 919-966-5136

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.